share_log

Xilio Therapeutics To Present Initial Phase 1C Dose Escalation Data For XTX101 In Combination With Atezolizumab In Late-Breaker Poster At SITC 39th Annual Meeting

Benzinga ·  Oct 30 09:25
Xilio Therapeutics To Present Initial Phase 1C Dose Escalation Data For XTX101 In Combination With Atezolizumab In Late-Breaker Poster At SITC 39th Annual Meeting
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment